Sandbox:Mitra: Difference between revisions

Jump to navigation Jump to search
No edit summary
(Blanked the page)
Tag: Blanking
Line 1: Line 1:
{{familytree/start}}
{{familytree | | | | | | | | | | | | | A01 | | | | | | | | | | |A01= <div style="float: Center; text-align: Center; width: 20em; padding:1em;"> '''Therapuetic Considerations in [[Right Ventriculay Myocardial Infarction]] ([[RVMI]])'''| | | |}}
{{familytree  | | | | | | | | | | || | |!| | | | | | | | | | | | | | |}}
{{familytree | | | |,|-|-|-|-|v|-|-|-|-|+|-|-|-|v|-|-|-|v|-|-|-|-|.| |}}
{{familytree | | | |!| | | | |!| | | | |!| | | |!| | | |!| | | | |!| |}}
{{familytree | | | B01 | | | B02 | | | B03 | | B04 | | B05 | | | B06 |B01=<div style="float: Center; text-align: Center; width: 5em; padding:1em;">'''[[Reperfusion]]'''|B02=<div style="float: Center; text-align: Center; width: 5em; padding:1em;">'''Maintenance of [[RV]] [[preload]]'''|B03=<div style="float: center; text-align: center; width: 5em; padding:1em;">'''Decreasing [[RV]] [[afterload]]'''|B04=<div style="float: Center; text-align: Center; width: 5em; padding:1em;">'''Restoring [[Rate]]/[[Rhythm]] and [[AV synchrony]]'''|B05=<div style="float: Center; text-align: Center; width: 5em; padding:1em;">'''Inotropic support'''|B06=<div style="float: Center; text-align: Center; width: 5em; padding:1em;">'''[[Mechanical Circulatory Support]]'''}}
{{familytree | | | |!| | | | |!| | | | |!| | | |!| | | |!| | | | |!| | | |}}
{{familytree | | | C01 | | | C02 | | | C03 | | C04 | | C05 | | | C06 |C01=<div style="float: Center; text-align: Center; width: 5em; padding:3em;">'''[[Thrmobolytics]]''' <br>'''[[Percutaneous coronary intervention]] ([[PCI]])''' <br>
|C02= <div style="float: Center; text-align: left;"> • '''Avoidance of preload-reducing agents''', such as:<br>
:❑ [[Nitrates]]
:❑ [[Diuretics]]
:❑ [[Morphin]]
• '''In patients with [[hypotension]] (without [[pulmonary congestion]]):
:❑ Intravenous administration of Fluids ([[N/S]] 0.9% at 40mL/min for up to 2L, to maintain [[CVP]] <15 mmHg and [[PCWP]] between 18-24 mmHg)
|C03=<div style="float: Center; text-align: left;"> • '''Systemic or pulmonary [[vasodilators]]:'''<br>
:❑ [[Nitrosrusside]]
:❑ Inhaled [[nitric oxide]]
|C04=<div style="float: Center; text-align: left;"> • '''In patients with [[bradyarrhthmias]]:'''<br>
:❑ [[Atropine]]
:❑ [[Pacemaker]]
• '''In patients with atrioventricular block:'''<br>
:❑ Temporary dual-chamber [[pacemaker]]
|C05=<div style="float: Center; text-align: left;"> '''In patients with refractory [[hypotension]]:'''<br> 
:❑ [[Dobutamine]] (along with fluids)
:❑ Other [[inotropes]]:
* [[Milrinone]]
* [[Norepinephrine]]
|C06= <div style="float: Center; text-align: left;"> • '''May be needed in patients with [[cardiogenic shock]] secondary to [[RVMI]]''':
:❑ Direct RV support
:❑ Indirect RV support
:❑ Biventricular support}}
<br><br>
{{familytree/end}}


==Do's==
* [[Right ventricular myocardial infarction]] [[(RVMI)]] should be ruled out in all patients presenting with acute [[inferior wall myocardial infarction]], in particular in patients with [[hypotension]].
*In patients presenting with [[chest pain]] and clinical findings of [[hypotension]], elevated [[JVP]] and clear lung fields, consider the differential diagnoses of [[RVMI]]. These include:
**[[Pulmonary embolism]]
**[[Pericarditis]] with [[pericardial tamponade]]
*Systemic or pulmonary [[vasodilators]] may be considered in selected patients to reduce [[RV afterload]], thereby improving [[cardiac output]].
*In patients with severe [[tricuspid regurgitation]] due to [[RVMI]], replacement of [[tricuspid valve]] or repair of the valve with annuloplasty rings may be considered.
*In patients with [[RVMI]] who have unexplained [[hypoxemia]] despite administration of 100% oxygen, [[right-to-left shunting]] -through a [[patent foramen ovale]] or [[atrial septal defect]]-, caused by the disproportionate elevation in right-sided filling pressures compared to the normal or slightly increased left-sided filling pressures should be considered.
*Patients with extensive [[necrosis]] due to [[RVMI]] may be at higher risk of [[right ventricular]] perforation during interventional procedures. [[Right ventricular catheterization]] or [[pacemaker]] insertion should be performed with great care in these patients.
==Don'ts==
* In patients with [[RVMI]], avoid preload-reducing agents such as [[nitrates]], [[diuretics]], [[morphine]], [[beta-blockers]], and [[calcium channel blockers]].
Previously:
{{Family tree/start}}
{{familytree | A01 | A01= <div style="float: left; text-align: left; width: 35em; padding:1em;"> '''Consider right ventricular MI in case of:'''
❑ [[Hypotension]]<br>
❑ Elevated [[jugular venous pressure]]<br>
❑ Clear lung fields<br>
❑ [[ECG]] changes suggestive of an [[inferior MI]] <br>
:❑ ST elevation in leads [[Echocardiogram#Limb Leads|II]], [[Echocardiogram#Limb Leads|III]] and [[Echocardiogram#Limb Leads|aVF]] </div>}}
{{familytree | |!| | }}
{{familytree | B01 | B01= <div style="float: left; text-align: left; width: 35em; padding:1em;">'''Order a right sided ECG in all patients with ST elevation in leads [[II]], [[III]] and [[aVF]]''' <br>
❑ Clearly label the [[ECG]] as right sided to minimize confusion in the emergency room and cath lab<br>
❑ ST-segment elevation of >1 mm in lead V4R suggests a right ventricular [[MI]]</div>}}
{{familytree | |!| | }}
{{familytree | C01 | C01=<div style="float: left; text-align: left; width: 35em; padding:1em;">
❑ Do not delay the decision and initiation of [[PCI]] vs [[fibrinolytic therapy]]<br>
❑ Do not administer:
:❑ [[Beta blockers]]
:❑ [[Nitrates]]
:❑ [[Diuretics]]
❑ Increase the [[right ventricle]] load by volume expansion with [[normal saline]] preferably with invasive monitoring
:❑ If central hemodynamic monitoring is available, administer normal saline (40 ml/min, up to a total of 2 L, intravenously) until there is an increase in the pulmonary capillary wedge pressure to approximately 15 mmHg <ref name="pmid24222834">{{cite journal| author=Inohara T, Kohsaka S, Fukuda K, Menon V| title=The challenges in the management of right ventricular infarction. | journal=Eur Heart J Acute Cardiovasc Care | year= 2013 | volume= 2 | issue= 3 | pages= 226-34 | pmid=24222834 | doi=10.1177/2048872613490122 | pmc=PMC3821821 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24222834  }} </ref>
:❑ If central hemodynamic monitoring in not available, administer normal saline with a close monitoring of the blood pressure </div>}}
{{familytree | |!| | }}
{{familytree | D01 | D01= <div style="float: left; text-align: left; width: 35em; padding:1em;"> '''If hypotension is not corrected with 1-2 L normal saline:'''
❑ Administer inotropic agents
: ❑&nbsp;&nbsp;[[Norepinephrine|<span style="color: #000000;">Norepinephrine</span>]]
:: ❑&nbsp;&nbsp;Initial dose: 0.5–1.0 μg/min
:: ❑&nbsp;&nbsp;Maximum dose: 30–40 μg/min
:: ❑&nbsp;&nbsp;Titrate to [[SBP|<span style="color: #000000;">SBP</span>]] &gt;90 mm Hg
: ❑&nbsp;&nbsp;[[Dopamine|<span style="color: #000000;">Dopamine</span>]]
:: ❑&nbsp;&nbsp;Cardiac dose: 5.0–10 μg/kg/min
:: ❑&nbsp;&nbsp;Pressor dose: 10–20 μg/kg/min
:: ❑&nbsp;&nbsp;Maximum dose: 20–50 μg/kg/min
: ❑&nbsp;&nbsp;[[Dobutamine|<span style="color: #000000;">Dobutamine</span>]]
:: ❑&nbsp;&nbsp;Usual dose: 2.0–20 μg/kg/min
:: ❑&nbsp;&nbsp;Maximum dose: 40 μg/kg/min
:: ❑&nbsp;&nbsp;Avoid ↑ HR by >10% of baseline
: ❑&nbsp;&nbsp;[[Milrinone|<span style="color: #000000;">Milrinone</span>]]
:: ❑&nbsp;&nbsp;Loading dose: 50 μg/kg (slowly over 10 minutes)
:: ❑&nbsp;&nbsp;Maintenance dose: 0.375–0.75 μg/kg/min
❑ Initiate hemodynamic monitoring with a [[pulmonary catheter]] if possible
</div>}}
{{Familytree/end}}

Revision as of 11:33, 25 August 2020